Introduction
Mutations in the SCN1A gene encoding voltage-gated sodium channels cause a variety of dominantly inherited epilepsy syndromes including generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy (SMEI). 1, 2 Most mutations that cause GEFS+ are missense and are presumed to result in a milder phenotype by altering the sodium channel activity, whereas mutations associated with SMEI result in loss of function of the channel. 1, 3 Given that a loss of function mutation can sometimes be associated with a milder phenotype, mutation type cannot reliably predict a severe outcome. 4 We report on a novel variant in the SCN1A gene segregating dominantly with a variable epilepsy phenotype.
Methods and case studies

Presentation of the propositus
The propositus presented at nine months of age with focal seizures with secondary generalization lasting for 15 min. He had a two day history of rhinorrhea and fever. The seizures stopped with the use of diazepam and the infant was discharged without anti-epileptic medications. He presented again at eleven months of age with twitching of his left arm that progressed to generalized tonic clonic seizures that lasted for 10 min. He had been previously well and had not been febrile. An EEG revealed sharp waves localized to the left anterior quadrant, infrequently seen at P3 > C3, F3. He was initially placed on phenobarbital, but due to the development of a rash, phenobarbital was stopped and he was started on clobazam. An EEG at twenty-five months of age revealed generalized bursts of spike and slow wave activity and rare left frontal sharp waves. At twenty-seven months of age he presented with a cluster of four generalized seizures. He was febrile with a two day history of an upper respiratory tract infection. Treatment with valproic acid was started and clobazam was discontinued. However, the patient developed thrombocytopenia necessitating the discontinuation of valproic acid and the initiation of treatment with keppra. As seizure control was poor, treatment was changed to stiripentol plus clobazam yielding an excellent clinical response. A repeat EEG at thirty months of age was normal.
Family history
Our patient was the first born to a nineteen year-old mother of Cambodian descent and a twenty-five year-old father of Filipino descent. The pregnancy, perinatal and neonatal histories were unremarkable. The parents are not consanguineous. There was a family history of seizures in the patient's mother, one of his maternal aunts, and one of her sons (Fig. 1) . The mother suffered from tonic clonic seizures since four years of age which continue to be well-controlled with valproic acid treatment. The maternal aunt has had grand mal seizures since infancy. She has been seizure free since treatment with valproic acid was initiated at twelve years of age. During the maternal aunt's two pregnancies, seizure control worsened after switching her to carbamazepine. Her oldest son is healthy while her youngest son experienced febrile seizures at six months of age. The other maternal aunt and the maternal uncle have no history of seizures. Mutations in the SCN1A gene can cause a variety of dominantly inherited epilepsy syndromes. Severe phenotypes usually result from loss of function mutations, whereas missense mutations cause a milder phenotype by altering the sodium channel activity. We report on a novel missense variant (p.Val1379Leu) in the SCN1A gene segregating in an autosomal dominant pattern in a family exhibiting a variable epilepsy phenotype ranging from generalized epilepsy with febrile seizures during infancy to a well controlled seizure disorder in adulthood. This report supports the importance of SCN1A mutation analysis in families in which seizure disorders segregate in an autosomal dominant fashion.
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Examination findings
On examination at thirty-six months of age the propositus appeared to have no dysmorphic features. His growth parameters revealed a weight of 16.4 kg (50th-75th percentile), a height of 98 cm (25th percentile) and an OFC of 49.3 cm (25th-50th percentile). His systemic examination was unremarkable. At thirty-eight months of age his gross motor skills were age appropriate, his fine motor skills were at a thirty month level and his language skills were delayed at a twenty-four month level.
Investigations and diagnostic process
An extensive work-up was initiated to investigate the cause of his seizures and developmental delay. These included a brain MRI scan, capillary and CSF lactate, plasma amino acids, urine organic acids, urine succinylpurine, urine thiosulfate, biotinidase enzyme assay, plasma acylcarnitine profile, CSF protein, amino acids and glucose and a chromosome analysis. These investigations were normal.
Based on the child's history of febrile and generalized seizures and the significant family history, a diagnosis of generalized epilepsy with febrile seizures plus (GEFS+) was entertained and sequencing of the SCN1A gene was initiated. Using genomic DNA obtained from whole blood, the 26 amplicons of the SCN1A gene were amplified and scanned by dHPLC for heterozygous mutations. Bidirectional sequence analysis was used to confirm any positive findings by the dHPLC analysis. A previously unreported unknown variant, c.4135G > T, which leads to the missense mutation, p.Val1379Leu, was detected in the pore region of the SCN1A gene (NM_006920.4). To further elucidate the potential pathogenicity of this variant, blood samples were obtained from all available family members; both those who have had seizures and those who were unaffected (Fig. 1) . The mother and the affected maternal first cousin were found to be heterozygous for this p.Val1379Leu variant. The affected maternal first cousin's mother is inferred to be an obligate carrier. Unaffected family members including the maternal aunt, the maternal uncle and a maternal first cousin did not carry this specific variant. The maternal grandparents were unavailable for testing and their medical histories were unknown.
Discussion
Generalized epilepsy with febrile seizures plus (GEFS+) is characterized by an autosomal dominant mode of inheritance with variable expressivity and incomplete penetrance. 2, 3, 5 Although the range of severity in this type of SCN1A related disorder is wide, in general the seizure phenotypes in affected families tend to be mild. 2 The more severe seizure types are thought to be associated with reproductive disadvantage and hence are less likely to be recognized as familial. 6 Affected individuals within a family with GEFS+ often present with febrile seizures (FS) in early childhood followed by occasional tonic, clonic, myoclonic, or absence seizures which respond to medication and remit by late childhood or early adolescence. Our family's presentation is consistent with this phenotype. The two sisters who had generalized seizures from early infancy have a relatively mild phenotype with good control on monotherapy especially in later adolescence. It is noteworthy that the maternal aunt's seizures worsened during her pregnancies following changing her medication from valproic acid to carbamazepine. Liao et al., 7 reported that mutations in the pore region of the SCN1A gene cause loss-of-function or partial loss-of-function of the sodium channel. This may explain why sodium channel blocker antiepileptic medications, including carbemazepine, may cause seizure control to worsen, as experienced by our patient. 7 Three affected family members from two generations were found to be heterozygous for this variant. The affected maternal aunt was inferred to be an obligate carrier. The three unaffected family members who were available for testing did not carry this variant. Based on segregation analysis, the likelihood of this variant co-segregating with the seizure disorder phenotype is 1000-1. It is possible that there are other explanations for the findings in this family and perhaps another undetected mutation closely linked to the variant is responsible for the phenotype. However, it is compelling to note that the valine at codon 1379 is highly conserved across the animal species including rhesus monkey and mouse. Mutation Taster 8 and SIFT 9 programs predict this single amino acid change to be disease-causing, whereas a third in silico program, PolyPhen, 10 predicts this variant to be benign. The presence of a missense mutation as opposed to a more severe truncating mutation, and the substitution of an amino acid with similar polarity and hydrophobicity are consistent with the milder GEFS+ phenotype seen in this family, as previously reported. 7 We conclude that with the current evidence and in particular the segregation analysis along with a change to the highly conserved valine, it is likely that the c.4135G > T [p.Val1397Leu] variant is responsible for this seizure-related phenotype in this family.
